Background: Astaxanthin is of carotenoids group which possess strong antioxidant properties. The present study was conducted to evaluate the hepatoprotective effects of astaxanthin in carbon tetrachloride (CCl 4 )-treated rats. Materials and Methods: Female Long-Evans rats were administered with CCl 4 orally (1 ml/kg) twice a week for 2 weeks and were treated with astaxanthin (10 mg/kg) every day for 2 weeks. Blood plasma samples were isolated from each group and were analyzed for alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase activities. Oxidative stress parameters such as malondialdehyde (MDA), nitric oxide (NO), and advanced protein oxidation product (APOP) were measured. Several enzyme functions such as myeloperoxidase (MPO), superoxide dismutase (SOD), and catalase (CAT) activities in the plasma and liver tissues were also analyzed. Moreover, inflammation and tissue fibrosis were also confirmed by histological staining of liver tissues. Results: This investigation revealed that CCl 4 administration in rats increased plasma AST, ALT, and ALP activities which were normalized by astaxanthin treatment. Moreover, CCl 4 administration increased as MDA, NO, and APOP level both in plasma and tissues compared to control rats. Astaxanthin also exhibited a significant reduction of those parameters in CCl 4 -administered rats. Astaxanthin treatment also restored the CAT and SOD activities and lowered MPO activity in CCl 4 -administered rats. Histological assessment also revealed that the astaxanthin prevented the inflammatory cells infiltration, decreased free iron deposition, and fibrosis in liver of CCl 4 -administered rats. Conclusion: These results suggest that astaxanthin protects liver damage induced by CCl 4 by inhibiting lipid peroxidation and stimulating the cellular antioxidant system.
INTRODUCTION
Liver is the most important internal organ within the human frame playing a vital role in metabolism and detoxification of a variety of drugs and xenobiotics. Thus, liver is susceptible to a wide range of toxic, microbial, metabolic, circulatory, and neoplastic insults. [1] Liver diseases are very common worldwide problem. Liver cirrhosis is an irreversible stage in the process of liver damage that occurs after liver fibrosis. Liver fibrosis is attributed to inflammation, excessive accumulation of extracellular matrix (ECM), and tissue remodeling under wound healing. [2] Chronic hepatitis and liver cirrhosis are positively associated with the occurrence of hepatocellular carcinoma. [3, 4] Therefore, the inhibition of hepatic inflammation and fibrosis is crucial in preventing the occurrence of liver cirrhosis and hepatocellular carcinoma. Several researches reported that free radicals and reactive oxygen species (ROS) play a pivotal role in the various steps that initiate and regulate the progression of liver fibrosis independently. [5, 6] Various xenobiotics are known to cause hepatotoxicity; one among them is carbon tetrachloride (CCl 4 ). [7] CCl 4 is usually used experimentally to induce liver injury, fibrosis, and carcinoma in rodents. A single dose of CCl 4 leads to centrizonal necrosis and steatosis, [8] while repeated S85
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Hepatoprotective Activity of Astaxanthin administration leads to liver fibrosis, cirrhosis, and hepatocellular carcinoma. [9] CCl 4 induces the production of several types of ROS. [10] Hepatotoxicity of CCl 4 involves its biotransformation into free radicals such as trichloromethyl free radical (CCl 3 ) and trichloroperoxyl radical, which may increase lipid peroxidation. [11] The current researches are now directed toward finding naturally occurring antioxidants, which might help prevent oxidative damage. Astaxanthin, a kind of carotenoid pigment naturally produced by algae, bacteria, and phytoplankton, contains conjugated double bonds, hydroxyl and ketone groups, involved in electron transfer and possesses free radicals scavenging activity. [12] Earlier reports showed that astaxanthin can scavenge peroxyl radicals and destroys peroxides, thereby protecting biological membranes from lipid peroxidation. [13, 14] Several studies also suggest that astaxanthin has a protective effect against oxidative stress, inflammation, and metabolic disorders, such as type 2 diabetes and cardiovascular diseases, in experimental animals [15] [16] [17] and humans. [18] It was previously demonstrated that astaxanthin could attenuate both lung fibrosis and renal fibrosis. [19] A recent report also suggests that astaxanthin ameliorated liver damage and fibrosis by decreasing the expression of nuclear factor kappa B (NF-κB) and transforming growth factor 1 (TGF-1) and maintained the balance between matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 1 in the liver of mice. [20] In this investigation, liver fibrosis was induced by bile duct ligation in mice and using CCl 4 administration intraperitoneally for a long period (2 months). Long-term CCl 4 administration in animal developed fibrosis of liver; however, time frame for the initiation of fibrosis is important and needs to be addressed. Moreover, astaxanthin effect on antioxidant defense in damaged liver tissue by short-term CCl 4 administration was not addressed properly before. Our recent investigations showed that antioxidant-rich fraction of plant powder ameliorated the oxidative stress, inflammatory insult, and fibrosis in liver of CCl 4 -administered rats. [21, 22] However, the effect of astaxanthin on oxidative stress, iron deposition, and inflammation in liver damage was poorly understood. Therefore, the present study was conducted to elucidate the effect of astaxanthin on oxidative stress and hepatic damage in CCl 4 -induced rats. Moreover, the effect of astaxanthin on inflammatory cells infiltration, iron deposition, and prevention of early development of fibrosis in liver of CCl 4 -induced rats was also addressed.
MATERIALS AND METHODS Chemicals
CCl 4 was obtained from Merck (Germany) and astaxanthin was obtained from the General Pharmaceutical Limited (Dhaka, Bangladesh). Thiobarbituric acid (TBA) was purchased from Sigma Chemical Company (USA). Trichloroacetic acid (TCA) was purchased from J. I. Baker (USA). Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) assay kits were obtained from DCI Diagnostics (Budapest, Hungary). Sodium hydroxide was collected from Merck (Germany). All other chemicals and reagents used were of analytical grade.
Animals and treatment
Twenty-four 10-12-week-old Long-Evans female rats (150-180 g) were obtained from the Animal Production Unit of Animal House at the Department of Pharmaceutical Sciences, North South University, and were kept in individual cages at room temperature of 25°C ± 3°C with a 12-h dark/light cycles. They have free access to standard laboratory feed (pellet food crushed to coarse powder) and water, according to the study protocol approved by the Ethical Committee of Department of Pharmaceutical Sciences, North South University, for animal care and experimentation.
To study the hepatoprotective effects of astaxanthin, rats were equally divided into four groups (six rats in each group).
• The weighed quantity of astaxanthin was dissolved in olive oil. Olive oil was chosen as the vehicle because astaxanthin is soluble in olive oil. The dose of astaxanthin (10 mg/kg) was selected on the basis of previously published literature survey, which showed a wide range of doses used in various investigations. Animals were checked for the body weight gain and measured the food and water intake on a daily basis. After 2 weeks, all animals were anesthetized using ketamine and pentobarbitone, sacrificed, and collected the blood and organs such as heart, kidney, spleen, and liver. Immediately after collection of the organs, they are weighted and stored at −20°C for further studies. Blood was drawn through syringe and centrifuged at 8000 rpm for 15 min at 4°C. Then, serum was transferred using a micropipette into microcentrifuge tubes (Eppendorf, Tarsons Products Pvt., Ltd., Kolkata, India) and stored at −20°C until analyzed.
Assessment of hepatotoxicity
Liver marker enzymes (ALT, AST, and ALP) were estimated in plasma using Diatec Diagnostic Kits (Hungary) according to the manufacturer's protocol.
Preparation of tissue sample for the assessment of oxidative stress markers
For determination of oxidative stress markers, liver tissue was homogenized in 10 volumes of phosphate buffer containing pH 7.4 and centrifuged at 8000 rpm for 15 min at 4°C. The supernatant was collected and used for the determination of protein and enzymatic studies as described below.
Estimation of lipid peroxidation
Lipid peroxidation in the liver was estimated calorimetrically measuring TBA reactive substances, followed by previously described method. [23] In brief, 0.1 ml of tissue homogenate (Tris-HCl buffer, pH 7.5) was treated with 2 ml of (1:1:1 ratio) TBA-TCA-HCl reagent (0.37% TBA, 0.25 N HCl, and 15% TCA) and placed in hot water bath for 15 min and cooled. The absorbance of clear supernatant was measured against reference blank at 535 nm.
Assay of nitric oxide
Nitric oxide (NO) was determined according to the method described by Tracey et al. as nitrate. [24] In this study, Griess-Illosvoy reagent was modified using naphthyl ethylene diamine dihydrochloride (0.1% w/v) instead of 1-naphthylamine (5%). The reaction mixture (3 mL) containing brain homogenates (2 mL) and phosphate buffer saline (0.5 mL) was incubated at 25°C for 150 min. Rest of process was MD. ARIFUL ISLAM, et al.: Hepatoprotective Activity of Astaxanthin followed as described in previous experiment of NO scavenging assay of the extract. A pink-colored chromophore was formed in diffused light. The absorbance of these solutions was measured at 540 nm against the corresponding blank solutions. NO level was measured using standard curve and expressed as nmol/g of tissue.
Advanced protein oxidation products assay
Determination of advanced protein oxidation products (APOPs) level was performed by modification of the method of Witko-Sarsat et al. [25] and Tiwari et al. [26] Two milliliters of plasma was diluted 1:5 in phosphate buffered saline (PBS); 0.1 mL of 1.16 M potassium iodide was then added to each tube, followed by 0.2 mL acetic acid after 2 min. The absorbance of the reaction mixture was immediately read at 340 nm against a blank containing 2 mL of PBS, 0.1 mL of KI, and 0.2 mL of acetic acid. The chloramine-T 7 absorbance at 340 nm was found linear within the range of 0-100 nmol/mL, AOPP concentrations were expressed as nmol/mL chloramine-T equivalents.
Catalase assay
Catalase (CAT) activities were determined using previously described method by Khan.
[27] The reaction solution of CAT activities contained 2.5 ml of 50 mmol phosphate buffer (pH 5.0), 0.4 ml of 5.9 mmol H 2 O 2 , and 0.1 ml enzyme extract. Changes in absorbance of the reaction solution at 240 nm were determined after 1 min. One unit of CAT activity was defined as an absorbance change of 0.01 as units/min.
Estimation of superoxide dismutase activity
Superoxide dismutase (SOD) was assayed in plasma and tissue homogenates using previously described method. [28] Three milliliters reaction mixture consisted of aliquot of enzyme preparation and PBS to make up the volume to 2.94 ml. The reaction was started by addition of 0.06 ml of 15 mM epinephrine. Change in absorbance was recorded at 480 nm for 1 min at 15 s interval. Control consisting of all the ingredients, except enzyme preparation, was run simultaneously. One unit of enzyme activity has been defined to cause 50% inhibition of autooxidation of epinephrine present in the assay system.
Estimation of myeloperoxidase activity
Myeloperoxidase (MPO) activity was determined by a dianisidine-H 2 O 2 method, [29] modified for 96-well plates. Briefly, plasma samples (10 μg protein) were added in triplicate. o-dianisidine dihydrochloride (Sigma) (0.53 mM) and H 2 O 2 (0.15 mM) in potassium phosphate buffer (50 mM) (pH 6.0) were also added to the sample mixture. The change in absorbance was measured at 460 nm. Results were expressed as units of MPO/mg protein.
Histopathological determination
For microscopic evaluation, liver tissues were fixed in neutral buffered formalin and embedded in paraffin, sectioned at 5 μm, and subsequently stained with hematoxylin and eosin, and Sirius red staining was also done to evaluate the inflammation, necrosis, and fibrosis in liver. Moreover, Prussian blue staining was also conducted to evaluate the iron deposition in liver section of rats. Sections were studied under light microscope at ×40 magnifications.
Statistical analysis
All values are expressed as mean ± standard error of mean. Statistical analysis was conducted by one-way analysis of variance followed by Newman-Keuls post hoc test using GraphPad Software, Inc. 7825 Fay Avenue, Suite 230 La Jolla, CA 92037 USA. Significant changes were considered as P < 0.05 in all cases.
RESULTS

Effect of astaxanthin on body weight, food, and water intake
Body weight of each rat was recorded every day during the experiment, and the percentage change was calculated for all groups. It was found that the body weight did not decrease significantly in CCl 4 -intoxicated rat group compared to the control rats. On the other hand, treatment of CCl 4 -intoxicated group with astaxanthin showed a significant increase in body weight compared to other groups [ Figure 1 ]. Besides, CCl 4 -intoxicated group showed decreased food and water intake compared to control rats [ Figure 1 and Table 1 ]. However, reduction of food and water intake was not improved by astaxanthin in CCl 4 -intoxicated group [ Figure 1 and Table 1 ].
Effect of astaxanthin on organ wet weights Table 1 shows the effect of CCl 4 treatments on the rats' organs wet weights. CCl 4 -treated rats showed slight decrease in liver wet weight compared to control rats; however, astaxanthin-treated rats did not improve in decreased liver wet weight compared to the control [ Table 1 ]. The wet weight of kidneys was not significantly changed due to CCl 4 administration and astaxanthin treatment among the groups studied [ Table 1 ]. The heart wet weight was also not changed significantly among the groups tested in this study. However, the wet weight of spleen was changed significantly in CCl 4 -treated rats compared to control rats (P < 0.05). Astaxanthin treatment in CCl 4 -treated rats normalized the spleen wet weight compared to CCl 4 -treated rats (P < 0.05).
Effect of astaxanthin on biochemical parameter of liver functions
To confirm the hepatic damage due to CCl 4 administration, we measured the liver marker enzyme activities in plasma. Biochemical measurement of liver functions revealed that CCl 4 induced a significant increase in plasma AST, ALT, and ALP activities compared to control rats (P < 0.05) [ Table 2 ]. Treatment of animals with astaxanthin every day for 2 weeks along with CCl 4 administration significantly counteracted the increased plasma AST, ALT, and ALP activities compared to the CCl 4 -intoxicated group [ Table 2 ]. In addition, treatment of animals with astaxanthin alone for 2 weeks did not show any significant change in liver enzymes compared to the control group, which signifies a nontoxic effect of this compound on liver [ Table 2 ].
Effect of astaxanthin on oxidative stress markers and antioxidant enzymes CCl 4 administration leads to the formation of free radicals after metabolism in the liver. Thus, increased lipid peroxidation and oxidative stress parameters required to be measured. To determine the oxidative stress in our study, we evaluated the malondialdehyde (MDA), NO, and APOP content in plasma and liver homogenates. CCl 4 -induced rats showed significant (P < 0.05) increased lipid peroxidation product MDA concentration both in plasma and liver homogenates compared to control group [ Table 2 ]. In addition, astaxanthin co-treatment significantly normalized the elevated level of MDA compared to CCl 4 -intoxicated group [ Table 2 ]. Astaxanthin treatment alone in Group III did not alter the MDA concentration compared to control rats [ Table 2 ]. In physiological system, NO is considered as beneficial; however, in oxidative stress, NO level increased significantly and may turn into peroxynitrate (•ONOO − ) production. In this study, NO was measured as nitrate, which was increased significantly both in plasma and liver homogenates compared to control rats (P < 0.05) [ Table 2 ]. Astaxanthin treatment in CCl 4 -intoxicated group normalized the elevated NO content in the plasma and liver homogenates [ Table 2 ]. Astaxanthin treatment Figure 1 : Effect of astaxanthin on body weight, food, and water intake in carbon tetrachloride-induced rats. Data are presented as mean ± standard error of mean, n = 6-7 or otherwise stated. Statistical analysis was conducted by one-way analysis of variance followed by Newman-Keuls post hoc test; significance was considered at P < 0.05 in all cases Table 2 ]. Further, CCl 4 administration has profound effect on APOP development in plasma and liver homogenates. CCl 4 challenge in rats significantly increased the APOP concentration in plasma and liver compared to control rats, which was decreased significantly due to astaxanthin treatment in CCl 4 -intoxicated rats (P < 0.05) [ Table 2 ]. Increased oxidative stress parameters could be result of decreased antioxidant defense in tissue level. Thus, tissue antioxidants such as SOD and CAT activities were measured in this study. CCl 4 -induced rats showed a significant decrease in liver antioxidant enzyme CAT and SOD activities, respectively, compared to the control rats (P < 0.05) [ Table 2 ]. It was also found that SOD and CAT activities were restored to near-normal by astaxanthin treatment in CCl 4 -intoxicated group compared to CCl 4 -toxicated group (P < 0.05) [ Table 2 ]. To determine inflammation and inflammatory cells infiltration in liver, we measured myeloperoxidase (MPO) activity in liver tissues. CCl 4 -intoxicated group rats showed significant increased MPO activity in liver compared to control rats [ Table 2 ]. Astaxanthin treatment significantly normalized the MPO activity compared to CCl 4 -intoxicated group (P < 0.05) [ Table 2 ]. These data are further supported by the histological assessment of tissue sections of liver. Figure 2h ]. Astaxanthin treatment in control rats also did not show any collagen deposition in liver [ Figure 2c ]. Furthermore, Prussian blue staining of liver sections was carried out to evaluate the free iron deposition in liver tissues. CCl 4 -induced rats showed that heavy iron droplets were deposited in liver section [ Figure 3a ] compared to control rats [ Figure 3b ], which was further normalized by astaxanthin treatment [ Figure 3d ]. Astaxanthin treatment in control rats also did not show any iron deposition in liver [ Figure 3c ].
Effect of astaxanthin on inflammation and fibrosis in the liver
DISCUSSION
Liver injury induced by CCl 4 is one of the best-characterized systems of xenobiotic-induced hepatotoxicity and commonly used model for the screening of hepatoprotective activity of different drugs. [30] Oxidative stress has been postulated as major molecular mechanism in hepatic damage induced by CCl 4 . [31] It is well known that CCl 4 is biotransformed by the cytochrome P450 system in the endoplasmic reticulum. The preliminary metabolite is the CCl 3 , which when combined with cellular lipids and proteins in the presence of oxygen forms trichloromethyl peroxy radical that may assault lipids at the membrane of endoplasmic reticulum quicker than CCl 3 . Consequently, trichloromethyl peroxy-free radical leads to cause lipid peroxidation. [30, 32] Free radicals formation and lipid peroxidation are the potent cellular mechanisms involved in the development of fatty liver caused by CCl 4 . [33] Antioxidants have been shown to possess a protective effect on liver fibrosis both in animal models and clinical trials. [21, 34] Our results suggest that astaxanthin possesses protective action against hepatic damages induced by CCl 4 . Serum hepatobiliary enzymes such as AST, ALT, and ALP are present in high concentrations under the disease conditions. When there is hepatocyte necrosis or membrane damage, these enzymes will be released into the circulation as indicated by elevated serum enzyme levels. [35] In the present study, the elevated levels of all these marker enzymes observed in CCl 4 -treated rats indicate liver damage. Treatment of astaxanthin to CCl 4 -induced rats ameliorated the toxic effects of CCl 4 and the above markers restored toward the normal level. This protective effect may be attributed to the free radical scavenging activity of astaxanthin, and results obtained in this study are in agreement with earlier findings. [21, 36] Hepatic damage and increased serum hepatobiliary enzymes activities are the end results of free radical-mediated oxidative stress in the liver. Increased oxidative stress has been attributed to the formation of reactive metabolites due to biotransformation of CCl 4 by cytochrome P4502E1. [37] Once formed, free radicals trigger a cascade of reactions that culminate in lipoperoxidation. [38] Lipid peroxidation product MDA and APOP will be generated eventually. Our investigations showed that MDA concentration was significantly increased in CCl 4 -treated group which was also reported in the previous studies. [21, 22] Astaxanthin treatment in CCl 4 -administered rats significantly declined the MDA concentration both in plasma and liver homogenates indicates antilipid peroxidative effects. In contrast to other carotenoids, 13 conjugated double bonds are present in astaxanthin structure which gives it a significantly greater antioxidant capacity. Polar hydroxyl groups are also present in the 3 and 3' positions of astaxanthin allowing it to sit near the lipid/water interface of the cell membrane bilayers where free radicals attack occur predominantly. [39] Thus, it can prevent chain reactions that occur when a fatty acid is oxidized. Increased free radicals may also trigger oxidation of other important components of cells such as proteins. Our investigation also showed that APOP concentration was also increased significantly in CCl 4 -treated rats, which was further normalized by astaxanthin treatment. This finding is in agreement with the previous report which suggests that antioxidant-rich food supplements can prevent protein oxidation and lowers APOP concentration in plasma and tissues of CCl 4 -administered rats. [21] Moreover, this investigation also suggests that astaxanthin treatment in CCl 4 -intoxicated group reduced the elevated NO concentration in plasma and liver of CCl 4 -treated rats. NO has been reported to be increased in liver cirrhosis. [40, 41] Some authors also proposed that a high level of NO is associated with CCl 4 -induced acute liver injury. [42] In presence of other free radicals such as superoxide radicals [•O 2 − ], NO converts into peroxynitrite radicals (•ONOO − ) which can react directly with thiol groups or with tyrosine hydroxyl groups on cellular enzymes and inactivates these enzymes. [43] Astaxanthin-mediated inhibition of NO production was also supported by the previous study. [16] Increased lipid peroxidation and oxidative stress are direct results of the diminishing antioxidant defense of the tissue. It was observed that the antioxidant SOD and CAT enzymes function lower significantly in chronic oxidative stress condition in liver of CCl 4 -administered rats. [44, 45] SOD is the main antioxidant enzyme that protects cells and tissues from the ROS generated from endogenous and exogenous sources. SOD also catalyzes mainly the conversion of superoxide anion [16, 46] Astaxanthin treatment in this study also improved and restored the SOD and CAT activities in plasma and liver significantly in CCl 4 -administered rats. Astaxanthin treatment also showed protecting effect of tissue damage by stimulating the cellular antioxidant enzymes, lowering lipid peroxidation, and protein oxidation against 2,3,7,8-tetrachloride benzo-p-dioxin-induced toxicity in rats. [47] This investigation suggests that carotenoid such as astaxanthin is useful in the prevention of oxidative stress-mediated tissue damage by upregulating the antioxidant enzymes. The nuclear factor erythroid 2-related factor 2 (Nrf2) is an important regulator of cellular resistance to oxidants and regulating transcription of antioxidants enzymes such as SOD and CAT. [48] Previous reports suggest that astaxanthin increased the nuclear translocation of Nrf2 and promoted the expression of antioxidant enzymes against oxidative stress. [49, 50] We propose that astaxanthin-mediated upregulation of antioxidant enzymes follows Nrf2-mediated pathways which need to be addressed properly in the future. Oxidative stress and lipid peroxidation-mediated hepatic cells damages may generate an inflammatory response, which was observed by infiltrating inflammatory cells alongside the blood vessels in the liver. [21, 34] Previous literature suggests that the infiltrating inflammatory cells are mainly monocyte and neutrophil in CCl 4 -induced liver damage in rats. [51, 52] CCl 4 metabolism-mediated free radicals' generation also stimulates the activation of Kupffer cells which release various inflammatory mediators such as tumor necrosis factor alpha (TNF-α) and interleukins. [53] These cytokines serve several aspects of inflammation such as synthesis of prostaglandins, macrophage activation, and the infiltration of neutrophil in inflamed area. [54, 55] The current study also showed that CCl 4 administration in rats develops inflammatory cells infiltration and an accumulation of extracellular collagen matrix around the scar site. The current observation is also supporting the biochemical finding which showed that MPO activity in liver tissue homogenates is also increased in CCl 4 -administered rats, which was further normalized by astaxanthin treatment. MPO is an important enzyme, released after recruitment and activation of neutrophils, and catalyze the formation of hypochlorous acid/hypochlorite and other oxidizing species. [56] In addition to the chronic inflammation, reactive oxidative species also play a critical role in the activation of hepatic stellate cells (HSCs) during liver fibrogenesis. Various cytokines, including TGF-β, TNF-α, and platelet-derived growth factor promote signaling for HSCs activation. [57] Activated Kupffer cells and ROS are other factors that are also responsible for the HSCs activation. [57, 58] Fibrogenic stimuli from TGF-β and ROS to activated HSCs result to excess production and deposition of abnormal ECM components in liver tissue. [58] Our investigation also revealed that CCl 4 -administered rats showed ECM deposition alongside the bile duct and central veins in liver which was further normalized by astaxanthin treatment. This finding in agreement with the recent report suggested that astaxanthin prevents hepatic fibrosis by decreasing the expression of NF-κB and TGF-β1. [20] Moreover, hepatic iron deposition was also found in CCl 4 -administered rats, which was further normalized by astaxanthin treatment. Free iron is a source of profibrogenic response in progressive liver fibrosis toward end-stage liver disease. [59] In fact, free iron deposition can trigger Fenton-like reaction in hepatocytes which produces notorious hydroxyl (•OH) free radicals.
CONCLUSION
From the above discussion, it can be concluded that astaxanthin contains significant hepatoprotective effect against CCl 4 -induced hepatotoxicity in rats. Astaxanthin-mediated protection against hepatic fibrosis, oxidative stress, and inflammation depends on the restoration of antioxidant enzymes, lowering lipid peroxidation, and decreased free iron deposition in hepatic tissues. Further investigations are warranted to elucidate the molecular mechanism of astaxanthin which may upregulate the antioxidant enzymes synthesis probably by Nrf2-mediated pathway.
